🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 04, 2026

Across 50 filings in the S&P 500 Consumer Discretionary stream (with cross-sector exposure via REITs, food/retail, and industrials), sentiment is predominantly mixed (14/50), reflecting revenue growth averaging +12% YoY in 18 earnings reporters (e.g., Sterling +92%, L.B. Foster +24%, Tyson +4.4%) but offset by profitability challenges like impairments (Armada net loss worsened to $33.3M) and volume declines (FreightCar -33%, OneWater -8.5%). Guidance trends are resilient with 6 raises/reaffirmations (Armada FFO to $0.51-$0.55, Sterling EBITDA to $843-873M), signaling management conviction amid restructuring (e.g., Armada $562M portfolio sale, $700M debt paydown). Capital allocation favors shareholders via $24.1M buybacks (Armada), dividends (Tyson $0.48, Superior $0.14, SmartStop $1.60 annualized), and M&A approvals (Farmer Bros 86.9% yes). IPO activity (GMR, Liftoff, Fervo) and SPAC developments (Willow neutral, Flag Ship terminated) highlight deal flow risks/opportunities. Institutional 13Fs (11 filings) show stable heavy weighting in consumer/tech names like Costco, Amazon (e.g., Garrison top Costco $10M). Portfolio-level: Margin expansion in winners (Marzetti + to 23.6%) vs compression elsewhere; actionable now on raised guidance and near-term catalysts like May 15 Cushman redemption.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 04, 2026

Across 50 filings in the USA S&P 500 Healthcare stream (with broader financial crossovers), mixed sentiment dominates healthcare/biotech names, with 4/7 key players (Twist, Vertex, Merck, Aura) showing YoY revenue growth averaging +12.8% (Twist +19%, Vertex +8%, Merck +4.9%) but widening net losses due to elevated R&D/SG&A (e.g., Twist net loss +12% YoY to $44M, Merck $4.2B loss from $8.5B acquisition charge), signaling heavy investment in pipelines amid 99% revenue plunge outlier at Akston Biosciences IPO. Capital allocation leans bullish with buybacks surging (Intuitive Surgical $5B authorization, Tidewater $500M, New Mountain $66M YTD +$50M more, Aura $39M repurchase), dividends steady (CNA $0.48, Corebridge $0.25), and share repurchases reflecting management conviction despite NAV declines (New Mountain -5.2% to $10.92). Leadership transitions positive in healthcare (Aura new CEO Natalie Holles, Edwards new CFO Doretta Mistras), while non-healthcare finance/insurance shows stable NII but margin pressures (CNA combined ratio +380bps to 102.2%, Loews net income -9%). Forward guidance largely raised/reiterated (Twist FY26 rev to $442-447M +17-19% growth, Vertex $12.95-13.1B), building H2 2026-2027 catalysts like Aura Phase 3 topline. 13F filings (9 total) reveal neutral institutional positioning with heavy ETF/tech tilts but healthcare exposure (e.g., Thermo Fisher, UnitedHealth). Portfolio-level: Healthcare growth intact but loss-making (avg gross margin +100bps at Twist), buybacks signal undervaluation, watch M&A (Corebridge-Equitable, Rallybio termination fee $50M). Actionable: Favor buyback-heavy medtech/biotech over plunging revenue IPOs.

17 high priority 33 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 04, 2026

Across these 10 DEF 14A proxy statements for US companies, a dominant theme is preparation for mid-June 2026 annual meetings, with 9/10 virtual and focused on routine governance items like director elections (all 10), say-on-pay advisory votes (8/10), and auditor ratifications (10/10), signaling stable board continuity amid executive compensation scrutiny. Financial highlights are sparse but reveal stark contrasts: National Vision Holdings stands out with FY2025 revenue +9.0% YoY to $1,987.5M, Adjusted Op Income +56.5% YoY to $102.5M (margin +5.2pp to 8.8%), and Adj EPS +53.8% YoY to $0.80, while STAAR Surgical reports a challenging FY2025 with slower growth and merger rejection but positive 2026 momentum from EVO+ exceeding expectations in China. Veeva Systems signals strong shareholder alignment via $2B buyback and engagement with 40% of shares, contrasting dilution risks in Wellgistics (blank check preferred) and Xos (plan expansion + note conversions >20% shares). Mixed/neutral sentiments prevail (7 neutral, 2 positive, 2 mixed), with no widespread insider trading or capital allocation shifts beyond Veeva's repurchase; portfolio-level trends show healthcare/tech firms prioritizing equity incentives amid governance enhancements like Helios' clawback policy. Market implications include low volatility from routine votes but alpha from outliers like National Vision's growth and STAAR's turnaround, with clustered catalysts in June 2026.

10 high priority 10 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 04, 2026

The IPO Pipeline stream features three S-1 filings dated May 4, 2026, dominated by dilutive resale registrations for Acurx Pharmaceuticals (two filings totaling ~2.95M shares) and a high-materiality SPAC IPO by Keystone Acquisition Corp ($250M base, up to $287.5M). No period-over-period financial trends (YoY/QoQ revenue/margins) are detailed, but pricing data reveals Acurx shares issued at low weighted average $3.07 post-Dec 2025 vs higher warrants ($7.25/$2.78), signaling share price pressure and funding desperation in biotech. Keystone's standard SPAC structure with founder shares at $0.003 highlights classic low-cost promotion potential. Overarching themes include biotech reliance on equity lines/warrants for working capital amid dilution risks (mixed/neutral sentiment), contrasted by resurgent SPAC activity. Critical implications: Acurx faces liquidity/price declines, while Keystone IPO could catalyze M&A hunting; portfolio-level pattern shows 2/3 filings as non-traditional 'IPOs' via resales, underscoring weak primary capital raise momentum.

3 high priority 3 total filings
· daily

Global High-Priority Regulatory Events — May 04, 2026

The 50 filings reveal a surge in high-priority events including positive insolvency resolutions (e.g., Embassy Developments quashing CIRP), a wave of IPO amendments in AI/tech/biotech (Cerebras, GMR Solutions, Fervo Energy), and active M&A/SPAC activity (GNL-Modiv merger, Blueport-SingAuto). Q1/FY2026 financials show mixed trends with average revenue growth of ~6-10% YoY across reporters (e.g., Berkshire +4.4%, Krystal +32%, National Vision +9%), but profitability volatile (Berkshire net earnings +119%, CNA -23%, Odyssey losses +15% YoY). Margin expansions in some (National Vision +520 bps) contrast compressions elsewhere, while capital returns include buybacks (Jagsonpal ₹40 Cr, Berkshire $235M treasury) and dividends. Indian filings highlight neutral board meetings and open offers amid insolvency risks, US-focused on IPOs/mergers with positive sentiment dominating (18/50 positive/mixed-positive). Portfolio-level: Industrials/real estate M&A bullish, biotech IPOs mixed on losses, no major insider selling patterns but leadership changes signal transitions. Implications: Near-term catalysts in earnings (May-Jun) and mergers offer alpha, watch delisting risks and trial readouts.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 04, 2026

Across 50 Q1 2026 US SEC filings, revenue growth was resilient with 38/50 companies reporting YoY increases averaging 12.5% (range 0.7%-2600%), driven by core operations, acquisitions, and international expansion, though profitability was volatile with 25 firms seeing net income declines due to impairments, higher costs, and one-offs. Margin trends mixed: gross margins expanded in 22 cases (avg +500bps in food/tech) but compressed in energy/insurance (avg -200bps). Capital allocation robust with $15B+ in dividends/buybacks (e.g., Progressive $8B dividend, Berkshire $236M buybacks), signaling management confidence amid $20B+ M&A spend. Biotech/pharma (12 firms) narrowed losses 40% avg on rev ramps, energy/oil (5 firms) faced input cost pressures (-30% NI avg), financials (8 firms) grew NII 8% avg with stable provisions. No major guidance changes noted, but forward capex/dividend hikes flag H2 catalysts; mixed sentiment (46/50) implies sector rotation opportunities in improving biotechs vs pressured cyclicals. Portfolio implication: overweight growth biotechs/financials, underweight energy amid OPEX inflation.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — May 04, 2026

Both Hoth Therapeutics and Jaguar Health face severe Nasdaq delisting risks, with negative sentiment and high materiality (9-10/10), highlighting a pattern of compliance failures in the biotech sector on the Nasdaq Capital Market. Hoth received a bid price deficiency notice for 30 consecutive days below $1.00 (March 18-April 29, 2026), granting 180 days until October 27, 2026, to cure, while Jaguar, post a 1-for-35 reverse stock split on April 30, 2026, failed the 500,000 publicly held shares requirement (only 401,226 shares), adding to its bid price issues and triggering a May 8, 2026, response deadline to the Hearings Panel. No period-over-period financial trends, revenue growth, or margin data provided in filings, focusing purely on regulatory halts risks; no insider trading activity, capital allocation changes (beyond reverse split), or M&A noted. Cross-company comparison shows Jaguar's situation more acute (materiality 10/10 vs 9/10) due to recent reverse split failure, signaling portfolio-level distress in low-float biotechs. Market implications include potential trading suspensions, delistings, and heightened volatility, urging avoidance or short strategies for exposed positions.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 04, 2026

Across 43 filings in the USA Corporate Distress & Bankruptcy stream, the dominant theme is proactive distress resolution through M&A (e.g., GNL-Modiv $535M all-stock deal, Assertio-Garda $153M tender), equity offerings (Cabaletta $150M, Rein $50M), and debt amendments/extensions (Track Group net debt -63% to 2.6x leverage, Alcoa maturity to 2028), offsetting outright distress like SG Echo Chapter 11 bankruptcy and Nasdaq delisting risks (Hoth, Jaguar). Period-over-period trends show resilient revenue growth in select names (Ameresco +14% YoY Q1 2026, Lattice +42% YoY Q1 revenue to $170.9M) but mixed profitability (Ameresco net loss widened to $18.3M YoY, Lattice op cash flow margin -10.1pp QoQ). Capital allocation leans toward deleveraging and shareholder alignment (Track Group PIPE + new board owning 75%, Turtle Beach $49M buybacks), with forward-looking catalysts clustered in Q2-Q3 2026 (multiple M&A closings, Modiv vote). Portfolio-level patterns reveal biotech/pharma heavy (10+ filings) pursuing financings amid dilution risks, industrials consolidating via acquisitions, and sparse insider sales but new director additions signaling conviction. Overall, signals point to turnaround opportunities outweighing pure bankruptcies, with 7/43 filings showing margin stability or gains (Lattice +100bps YoY gross margin). Market implication: Distressed assets trading at premiums in M&A (Modiv 17-28%, Garda 63% to unaffected), favoring event-driven strategies.

43 high priority 43 total filings
· daily

US Executive Officer Management Changes SEC — May 04, 2026

Across 45 filings in the USA Executive & Director Changes stream (33 new), a wave of 20+ CEO/CFO/executive transitions dominates, including 8 retirements/planned departures (e.g., Publix Executive Chairman, Occidental CEO, Exxon CAO, Pool Corp CEO, Adeia CEO) and 15+ appointments/promotions (e.g., Aura CEO, Hercules President/CFO, Edwards Lifesciences CFO from Viatris), signaling proactive leadership refreshes amid sector pressures. Financial trends where reported show mixed results: BDCs like New Mountain (NII flat YoY at $0.32/share, NAV -5% QoQ to $10.92) and Great Elm (NII +13% QoQ to $0.36/share but NAV -4% QoQ to $7.74) highlight portfolio volatility; Sonos Q2 rev +8% YoY to $282M with first positive EBITDA in 4 years; Pinterest Q1 rev +18% YoY to $1.008B but net loss widened to $74M. Capital allocation remains shareholder-friendly with repurchases (New Mountain $66M YTD +$50M auth, Great Elm 1% shares at 36% NAV discount, Intuitive $5B program increase) and dividends (Great Elm $0.25/share Q2, 18% yield). Positive sentiments in 60% of filings (e.g., hires with deep expertise), but mixed/neutral in departures; biotech hires (Aura, Pasithea, Tivic) tie to trial catalysts. Portfolio-level: Margin stability in consumer/tech offset by BDC NAV erosion; energy/retail transitions orderly. Implications: Opportunities in growth-oriented hires (biotech, semis), risks in BDC volatility and sudden CFO churn (5 cases).

45 high priority 45 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — May 04, 2026

The single filing in the USA Bankruptcy & Insolvency stream highlights a major distress event for Olenox Industries Inc. (formerly Safe & Green Holdings Corp., SGBX), as its wholly-owned subsidiary SG Echo LLC filed voluntary Chapter 11 on April 28, 2026, in the Eastern District of Oklahoma, triggering a $4M loan default stay. No period-over-period financial trends are detailed, but the bankruptcy underscores underlying operational or liquidity pressures absent from prior disclosures. Parent company operations continue normally with the subsidiary operating as debtor-in-possession (DIP), suggesting contained impact but high materiality (10/10) and negative sentiment. Market implications include potential sharp equity downside, heightened volatility, and short-term trading opportunities in distressed assets. Portfolio-level pattern: isolated subsidiary restructuring amid broader insolvency watchlist, with no cross-filing comparisons available.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 04, 2026

Across 45 filings on USA Board Room Changes from May 4, 2026, a dominant theme is C-suite and board transitions, with 18 CEO/President/CFO changes (9 appointments, 9 departures/retirements), 12 new director additions, and 8 annual meetings showing strong shareholder approval (avg 95%+ for directors/say-on-pay). Period-over-period trends reveal mixed financial health: revenue growth in 4/7 reporters (Sonos +8% YoY Q2, Pinterest +18% YoY Q1 avg ARPU +6%, GECC NII +13% QoQ Q1, New Mountain NII flat YoY), but NAV declines in BDCs (GECC -4% QoQ to $7.74, New Mountain -5% to $10.92) and losses (Sonos Q2 GAAP net loss $29M improved YoY, Pinterest Q1 loss widened to $74M). Capital allocation remains shareholder-friendly with $5B Intuitive Surgical buyback increase, $2B Pinterest repurchases, GECC $57.5M note calls/$0.5M share buyback, New Mountain $66M YTD repurchases +$50M auth. Positive biotech appointments (Aura, Tivic, Pasithea) bolster trials, while planned energy transitions (Occidental, Exxon, Publix) signal continuity. Implications: Opportunities in experienced leadership hires amid churn, risks from interim roles and NAV pressure in BDCs/fintech.

45 high priority 45 total filings
· daily

US Merger & Acquisition SEC Filings — May 04, 2026

The 18 filings reveal a surge in US M&A and takeover activity dominated by SPAC IPOs, de-SPAC approvals, and completed acquisitions across sectors like logistics, defense/AI, beverages, biotech, banking, and homebuilding, with 6 new SPAC-related IPOs/pricings and 5 deal completions signaling robust dealmaking in May 2026. Positive sentiment prevails in 12/18 filings, driven by unanimous board approvals, large IPO sizes ($100M-$350M), and strategic acquisitions enhancing footprints (e.g., SunOpta delisting post-$6.50/share buyout, Gyre's $300M all-stock Cullgen deal). Key period trends include GBTG's Q1 revenue +35% YoY (7% ex-acqs) but margin contraction (-410 bps gross, -490 bps EBITDA) amid a pending acquisition; no broad insider selling/buying noted, but capital allocation favors trust deposits for SPAC extensions (e.g., $13.9K-$498 into trusts). Portfolio-level patterns show SPACs extending deadlines (3 cases) or approving mergers with low/no redemptions (e.g., Willow Lane $134.5M trust intact), contrasting one termination and Nasdaq compliance risks. Implications: heightened M&A liquidity for targets, but execution risks from redemptions (19.6M in AParadise) and regulatory hurdles; watch SPAC closings by Q3 2026 for de-SPAC catalysts.

18 high priority 18 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 04, 2026

Overnight SEC filings reveal a surge in IPO amendments (e.g., GMR Solutions, Cerebras, Odyssey Therapeutics, Liftoff Mobile, Fervo Energy) signaling robust capital market activity in AI, biotech, and EMS sectors, with proposed valuations from $205M to multi-billion enterprises amid positive sentiment. Earnings reports show mixed Q1 2026 results: revenue growth averaging +7% YoY across reporters (Berkshire +4.4%, National Vision +9%, Norwegian Cruise +10%, Illumina +4.8%), but net income volatility with Berkshire +119% outlier versus Loews -9%, CNA -23%, and margin compressions in insurance (CNA combined ratio 102.2% vs 98.4% YoY). M&A activity dominates industrials/REITs with Global Net Lease-Modiv $535M all-stock deal at 17% premium, immediately 4% AFFO accretive, alongside SPAC combos (Willow Lane-Boost Run, Blueport-SingAuto). Biotech catalysts abound with Cabaletta data presentations May 14 and Aura Phase 3 enrollment on track for H2 2027 topline. 13F filings indicate sustained institutional conviction in tech megacaps (NVIDIA, MSFT, AAPL top across multiple filers). Portfolio-level trends: Revenue resilience but insurance margin pressures (3/5 insurers combined ratio >100%), capital raises via IPOs/SPACs outpacing buybacks/dividends. Implications: Pre-market bullish for IPO/SPAC names and M&A targets, cautious on insurers/cruisers amid guidance cuts.

28 high priority 22 medium 50 total filings
· daily

DHS Homeland Security Contracts — May 02, 2026

A single DHS contract totaling $9,401,259 in obligations was analyzed, representing 100% civilian activity with zero defense-related components. The U.S. Coast Guard awarded Lockheed Martin Corporation a sole-source, cost-plus-fixed-fee contract for C4ISR integration and test laboratory services, spanning May 2022 to May 2027 in Moorestown, NJ. This neutral signal (strength 3/10, materiality 2/10) adds modestly to Lockheed Martin's federal IT services portfolio (NAICS 541513, PSC DC01), with estimated annual revenue of ~$1.88M. The highest-conviction signal is low materiality relative to Lockheed's scale, providing minimal sector impact. A key risk/watch item is zero funds outlayed to date despite $9.4M obligated, alongside $1.15M in unexercised options.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — May 02, 2026

The analyzed contracts total $269,952,453 in obligations, representing a 100% civilian split with zero defense-related awards, dominated by HHS's Office of Assistant Secretary for Preparedness and Response (ASPR) via BARDA Ventures. GLOBAL HEALTH INVESTMENT CORPORATION, a New York-based nonprofit, secured this $269,952,453 firm fixed price Definitive Contract on 2021-05-25 for health R&D (NAICS 541715, PSC AN41), with $241,937,500 (90%) already outlayed over the initial performance period from 2021-06-01 to 2031-06-01. The highest-conviction signal is neutral (4/10 strength), highlighting sustained federal funding for long-term health preparedness R&D but limited direct appeal for equity portfolios due to the recipient's nonprofit status. A key risk is high contract pricing risk under the firm fixed price structure within the BARDA Ventures Other Transaction Agreement. Watch outlay progress on the remaining ~$28 million obligation toward the 2031 current end date or potential extension to 2041.

1 total filings
· daily

New Federal Contractors — May 02, 2026

This digest synthesizes $1,718,415,049 in total obligations across 5 new civilian federal contracts (0/5 defense-related) awarded primarily to DOE, USDA, HHS, GSA, and DHS, highlighting civilian agency commitments to nuclear materials production, IT software/support, health R&D, financial services, and C4ISR lab services. Dominant sector themes include strategic nuclear capacity buildup via DOE's $900M award to ORANO FEDERAL SERVICES LLC and sustained IT investments like USDA's $294.6M Salesforce deal with CARAHSOFT TECHNOLOGY CORP. The highest-conviction bullish signal is CARAHSOFT TECHNOLOGY CORP's fully obligated and outlayed $294.6M USDA contract (strength 8/10), signaling reliable revenue through 2025. Balanced by neutral signals for nonprofit GLOBAL HEALTH INVESTMENT CORPORATION ($270M HHS) and modest LOCKHEED MARTIN ($9.4M DHS). Key risk: High pricing risk on firm-fixed-price structures across top awards (ORANO, CARAHSOFT, GLOBAL HEALTH), with watch on initial outlays post-May 2026 starts.

5 total filings
· daily

Significant Contract Modifications ($10M+) — May 02, 2026

This digest covers five significant civilian contract modifications totaling $1,718,415,049 in obligations, with 0/5 defense-related awards across DOE, USDA, HHS, GSA, and DHS. Dominant themes include strategic nuclear materials production (DOE/ORANO $900M) and IT/software services (USDA/Carahsoft $295M), underscoring civilian agency commitments to energy security and enterprise tech upgrades. Highest-conviction bullish signal is Carahsoft Technology Corp's fully obligated and outlayed $294.6M USDA Salesforce contract (strength 8/10), signaling reliable revenue through 2025. Key risk is high pricing risk on firm-fixed-price structures across top awards (ORANO, Carahsoft, GLOBAL HEALTH), with watch on initial outlays for ORANO's LEU production post-May 2026 start.

5 total filings
· daily

Contract Deobligations Alert — May 02, 2026

This Contract Deobligations Alert synthesizes $1,718,415,049 in total obligations across 5 civilian contracts (0 defense-related) awarded by DOE, USDA, HHS, GSA, and DHS, highlighting sustained federal commitments in nuclear materials, IT software, health R&D, financial services, and C4ISR support. Dominant themes include DOE's $900M push for domestic LEU production via ORANO FEDERAL SERVICES LLC and USDA's $294.6M Salesforce investment with CARAHSOFT TECHNOLOGY CORP, both full and open competition firm-fixed price awards. Highest-conviction signal is bullish for CARAHSOFT (strength 8/10, materiality 9/10) given full obligation and outlays on a 5-year USDA IT contract. Balanced by neutral signals for nonprofit GLOBAL HEALTH INVESTMENT CORPORATION ($270M HHS R&D) and small Lockheed Martin ($9.4M DHS) addition. Key risk: High pricing risk on firm-fixed structures across top contracts, with watch on initial outlays for ORANO post-May 2026 start.

5 total filings
· daily

Contract Option Exercises — May 02, 2026

This digest covers five civilian agency contract option exercises totaling $1,718,415,049 in obligations, with zero defense-related awards, highlighting sustained federal investment in nuclear materials, IT software, health R&D, financial services, and DHS IT support. Dominant themes include DOE's $900M commitment to domestic low-enriched uranium production via ORANO FEDERAL SERVICES LLC and USDA's fully outlayed $295M Salesforce deployment with CARAHSOFT TECHNOLOGY CORP, representing the highest-conviction bullish signals at 8/10 strength. BANK OF NEW YORK MELLON's $244M GSA financial services contract adds steady revenue visibility with $189M already outlayed. Neutral signals from GLOBAL HEALTH INVESTMENT CORPORATION's $270M HHS health R&D and Lockheed Martin's modest $9M DHS C4ISR lab services temper overall momentum. Key risk is high pricing risk across firm-fixed-price structures, with watch on initial outlays for ORANO post-May 2026 start and performance milestones to 2033.

5 total filings
· daily

Federal IT & Cybersecurity Contracts — May 02, 2026

The single contract analyzed totals $294,589,912 in obligations, entirely civilian with zero defense exposure, centered on Department of Agriculture's enterprise-wide Salesforce software and support services via Carahsoft Technology Corp. This firm fixed-price delivery order, fully obligated and outlayed under full and open competition, provides a bullish signal for Carahsoft with high materiality (9/10) and strength (8/10), representing an estimated $58.9M in annual revenue through its 5-year performance period ending June 19, 2025. The dominant theme is USDA Office of the Chief Financial Officer's sustained IT modernization investment in NAICS 541519 and PSC 7030 categories. Highest-conviction signal is revenue visibility for Carahsoft in civilian federal IT reselling. Key watch item is the contract's performance end date of 2025-06-19 for potential follow-on opportunities amid high pricing execution risk.

1 total filings